Boston Scientific Corporation, a leading global medical technology company, is headquartered in the United States. Founded in 1979, the company has established itself as a key player in the medical device industry, focusing on innovative solutions across various therapeutic areas, including cardiovascular, rhythm management, and urology. With a strong presence in North America, Europe, and Asia-Pacific, Boston Scientific is renowned for its advanced products and services, such as minimally invasive devices and cutting-edge imaging technologies. The company’s commitment to innovation is exemplified by its numerous milestones, including the development of the first drug-eluting stent. Recognised for its market leadership, Boston Scientific continues to push the boundaries of medical technology, enhancing patient outcomes and improving quality of life. Its dedication to research and development positions it as a trusted partner in healthcare worldwide.
How does Boston Scientific's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Boston Scientific's score of 94 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Boston Scientific reported total carbon emissions of approximately 97,421,000 kg CO2e (Scope 1 and 2 combined) globally, with Scope 1 emissions at about 87,567,000 kg CO2e and Scope 2 emissions at approximately 9,854,000 kg CO2e. In the UK, the company recorded total emissions of about 4,067,000 kg CO2e, with Scope 1 emissions at approximately 883,000 kg CO2e, Scope 2 at 53,000 kg CO2e, and Scope 3 emissions at around 3,131,000 kg CO2e. Boston Scientific has set ambitious climate commitments, aiming for carbon neutrality in its manufacturing and key distribution sites by 2030. The company has achieved a significant reduction of 68% in greenhouse gas emissions (Scopes 1 and 2) since 2009. Furthermore, it has committed to a near-term target of reducing absolute Scope 1 and 2 GHG emissions by 46.2% by 2030 from a 2019 base year. Long-term goals include a 97% reduction in GHG emissions per USD value added by 2050, equivalent to a 90% absolute reduction. The company is also focused on Scope 3 emissions, targeting a 55% reduction per USD value added by 2030. Boston Scientific's climate strategy aligns with the Science Based Targets initiative (SBTi), committing to net-zero emissions across its value chain by 2050. This comprehensive approach underscores Boston Scientific's dedication to sustainability and reducing its environmental impact.
Access structured emissions data, company-specific emission factors, and source documents
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boston Scientific is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.